Alembic Pharmaceuticals Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2026 • Formulations: 83.8% • Active Pharmaceutical Ingredients (API): 16.2%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has consistently been profitable over the last 5 years
- Company has been maintaining a healthy dividend payout of 35.0%
- Company has a consistent dividend-paying track record
- Stock looks reasonably valued - P/E of 23.2 is below its historical median
- Company comfortably covers its interest (8.4x coverage)
- Company generates healthy free cash flow
CONS
- Company has delivered a poor profit growth of -9.7% over past five years
- Recurring exceptional / one-off items are inflating headline profit
- Operating margins have contracted to 7.8% from 12.6%
- Company has delivered a poor sales growth of 6.4% over past five years
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1868.50 | 37.06 | 448315.74 | 0.86 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9482.75 | 86.06 | 251737.22 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4931.90 | 86.01 | 187593.62 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1129.00 | 24.95 | 112618.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1368.00 | 32.79 | 110515.04 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1933.25 | 95.54 | 104455.86 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1690.00 | 26.19 | 97238.86 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2092.00 | 17.30 | 95660.02 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1143.20 | 29.61 | 95420.61 | 0.70 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2266.00 | 45.82 | 93596.02 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2439.55 | 38.29 | 68850.12 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| APLLTD | 817.80 | 23.18 | 16074.93 | 1.47 | 172.36 | 12.19 | 2149.77 | 25.66 | 11.74 | 15.46 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,486 | 1,595 | 1,631 | 1,517 | 1,562 | 1,648 | 1,693 | 1,770 | 1,711 | 1,910 | 1,876 | 1,848 | 2,150 | |
| 1,287 | 1,387 | 1,364 | 1,257 | 1,325 | 1,409 | 1,433 | 1,498 | 1,429 | 1,594 | 1,583 | 1,620 | 1,943 | |
| Operating Profit | 199 | 208 | 266 | 260 | 237 | 239 | 260 | 272 | 281 | 316 | 294 | 228 | 207 |
| OPM % | 13.37% | 13.06% | 16.34% | 17.14% | 15.16% | 14.52% | 15.37% | 15.37% | 16.45% | 16.53% | 15.64% | 12.34% | 9.61% |
| 12 | 10 | 3 | 4 | 2 | 30 | 10 | 14 | 6 | 7 | -27 | 1 | 15 | |
| Interest | 14 | 16 | 15 | 11 | 13 | 19 | 22 | 25 | 24 | 24 | 23 | 23 | 28 |
| Depreciation | 66 | 68 | 69 | 69 | 69 | 71 | 70 | 69 | 74 | 76 | 80 | 89 | 98 |
| Profit before Tax | 130 | 135 | 185 | 183 | 157 | 180 | 177 | 193 | 191 | 222 | 163 | 118 | 222 |
| Tax % | 7.06% | -1.43% | 2.24% | 2.53% | 14.35% | 15.19% | 22.59% | 18.33% | 19.14% | 18.00% | 18.09% | -70.56% | 22.31% |
| Net Profit | 0 | 0 | 0 | 0 | 135 | 153 | 138 | 157 | 154 | 184 | 132 | 202 | 172 |
| 6.14 | 6.95 | 9.18 | 9.07 | 6.84 | 7.79 | 7.01 | 7.98 | 7.85 | 9.40 | 6.76 | 10.31 | 8.80 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3,135 | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 6,229 | 6,672 | 7,345 | 7,784 | |
| 2,520 | 2,516 | 3,079 | 3,392 | 3,913 | 4,432 | 4,945 | 5,296 | 5,669 | 6,227 | 6,740 | |
| Operating Profit | 615 | 615 | 856 | 1,214 | 1,480 | 874 | 708 | 933 | 1,003 | 1,118 | 1,044 |
| OPM % | 19.61% | 19.65% | 21.75% | 26.36% | 27.44% | 16.48% | 12.53% | 14.97% | 15.03% | 15.22% | 13.41% |
| 3 | 35 | 27 | -30 | 87 | 50 | 3 | 29 | 61 | -12 | -4 | |
| Interest | 5 | 3 | 18 | 27 | 16 | 18 | 50 | 56 | 79 | 94 | 98 |
| Depreciation | 83 | 105 | 115 | 157 | 183 | 287 | 275 | 273 | 279 | 319 | 342 |
| Profit before Tax | 529 | 541 | 749 | 1,000 | 1,368 | 625 | 355 | 632 | 707 | 694 | 725 |
| Tax % | 23.09% | 22.24% | 20.92% | 19.92% | 18.52% | 16.70% | 3.55% | 2.53% | 17.70% | 3.33% | 4.99% |
| Net Profit | 407 | 421 | 593 | 801 | 1,115 | 521 | 342 | 616 | 582 | 671 | 689 |
| EPS | 21.39 | 21.89 | 31.00 | 43.97 | 59.18 | 26.50 | 17.40 | 31.33 | 29.68 | 34.33 | — |
| Dividend Payout % | 18.70% | 18.27% | 17.74% | 22.74% | 24.00% | 37.73% | 45.98% | 35.11% | 37.06% | 34.95% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 9%
- 5 Years:
- 6%
- 3 Years:
- 9%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- -1%
- 5 Years:
- -10%
- 3 Years:
- 25%
STOCK PRICE CAGR
- 10 Years:
- 3%
- 5 Years:
- 1%
- 3 Years:
- 2%
- 1 Year:
- -14%
RETURN ON EQUITY
- 10 Years:
- 18%
- 5 Years:
- 11%
- 3 Years:
- 12%
- Last Year:
- 12%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 38 | 38 | 38 | 38 | 39 | 39 | 39 | 39 | 39 | 39 |
| Minority Interest | 0 | 0 | -1 | -29 | 0 | 0 | 0 | 0 | -1 | -6 |
| 1,865 | 2,182 | 2,681 | 3,182 | 5,028 | 5,198 | 4,331 | 4,779 | 5,152 | 5,636 | |
| 89 | 708 | 928 | 1,821 | 271 | 502 | 705 | 493 | 1,242 | 1,565 | |
| Trade Payables | 501 | 759 | 644 | 626 | 669 | 706 | 680 | 736 | 880 | 835 |
| 319 | 376 | 661 | 554 | 954 | 784 | 308 | 294 | 397 | 516 | |
| Total Liabilities | 2,811 | 4,064 | 4,952 | 6,192 | 6,961 | 7,230 | 6,064 | 6,341 | 7,709 | 8,586 |
| 799 | 993 | 1,158 | 1,552 | 1,788 | 1,798 | 2,398 | 2,547 | 2,524 | 3,081 | |
| Capital Work in Progress | 369 | 911 | 1,341 | 1,574 | 1,944 | 2,206 | 601 | 524 | 837 | 634 |
| 50 | 42 | 49 | 18 | 236 | 118 | 96 | 93 | 127 | 141 | |
| 633 | 734 | 967 | 1,188 | 1,486 | 1,610 | 1,475 | 1,644 | 2,288 | 2,511 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,025 | 1,400 | 1,466 | |
| Cash & Bank | 160 | 90 | 206 | 81 | 106 | 69 | 82 | 127 | 90 | 203 |
| 800 | 1,294 | 1,230 | 1,780 | 1,400 | 1,429 | 1,410 | 382 | 443 | 551 | |
| Total Assets | 2,811 | 4,064 | 4,952 | 6,192 | 6,961 | 7,230 | 6,064 | 6,341 | 7,709 | 8,586 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 447 | 448 | 978 | 685 | 1,709 | 676 | 785 | 803 | 88 | 783 | |
| Cash from Investing | -486 | -884 | -756 | -732 | -839 | -372 | -448 | -321 | -568 | -506 |
| Cash from Financing | -129 | 503 | 59 | 155 | -597 | -217 | -262 | -438 | 444 | -164 |
| -286 | -69 | 115 | -128 | 27 | -37 | 14 | 45 | -37 | 113 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-07 - Alembic Pharmaceuticals Limited has informed the Exchange about General Updates: : Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Incorporation Of a Wholly Owned Subsidiary Company
2026-08-27 - Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of meet
2026-08-27 - Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of meet
2026-08-25 - Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-20 - Alembic Pharmaceuticals Limited has informed the Exchange about Change in Company Secretary/Compliance Officer
2026-08-11 - Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-10 - Alembic Pharmaceuticals Limited has informed the Exchange about Resignation of Director/KMP/SMP
2026-08-10 - Alembic Pharmaceuticals Limited has informed the Exchange regarding Resignation of Ms. Manisha Saraf as Company Secretary & Compliance Officer of the company w.e.f. August 11, 2026.
2026-08-10 - Alembic Pharmaceuticals Limited has informed the Exchange about Transcript
News
Recent coverage and analyst commentary for APLLTD
Loading news…
AI Stock Analyst
Alembic Pharmaceuticals Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account